Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inhibitors of CYP450 1A1 may theoretically increase the plasma concentrations of riociguat, which is partially metabolized by the isoenzyme to its main active metabolite (1/10th to 1/3rd the pharmacologic activity of riociguat). Increased levels of riociguat may increase the risk for hypotension.

MANAGEMENT: Caution is advised if riociguat is prescribed in combination with an inhibitor of CYP450 1A1. Blood pressure should be monitored, and a dose reduction of riociguat should be considered if necessary.

Chemical substances present in cigarette smoke may reduce the blood levels of riociguat. This means that the medication may be less effective if you smoke during treatment. Let your doctor know if you are a smoker, or if you start smoking or stop smoking during treatment with riociguat, because the dosage may need to be adjusted. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Food may affect the absorption and blood levels of riociguat. To avoid significant fluctuations in blood levels of the medication, riociguat should be taken about the same time each day consistently either with or without food.